Latest news with #SponsoredADR
Business Insider
4 days ago
- Business
- Business Insider
CFRA Sticks to Its Hold Rating for Trip.com Group Sponsored ADR (TCOM)
CFRA analyst Siti Salikin maintained a Hold rating on Group Sponsored ADR (TCOM – Research Report) today and set a price target of $65.00. The company's shares closed today at $61.75. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Salikin is a 3-star analyst with an average return of 21.3% and a 57.14% success rate. Currently, the analyst consensus on Group Sponsored ADR is a Strong Buy with an average price target of $77.00. The company has a one-year high of $77.18 and a one-year low of $38.23. Currently, Group Sponsored ADR has an average volume of 4.19M.
Business Insider
7 days ago
- Business
- Business Insider
Analysts' Top Healthcare Picks: Radiopharm Theranostics Limited Sponsored ADR (RADX), Mediwound (MDWD)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Radiopharm Theranostics Limited Sponsored ADR (RADX – Research Report) and Mediwound (MDWD – Research Report) with bullish sentiments. Confident Investing Starts Here: Radiopharm Theranostics Limited Sponsored ADR (RADX) JonesTrading analyst Justin Walsh reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR on May 22 and set a price target of $30.00. The company's shares closed last Friday at $4.81, close to its 52-week low of $3.55. According to Walsh is ranked 0 out of 5 stars with an average return of -5.4% and a 28.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Actinium Pharmaceuticals, and Perspective Therapeutics. The word on The Street in general, suggests a Hold analyst consensus rating for Radiopharm Theranostics Limited Sponsored ADR. Mediwound (MDWD) In a report issued on May 22, Michael Okunewitch from Maxim Group maintained a Buy rating on Mediwound, with a price target of $30.00. The company's shares closed last Friday at $20.37. According to Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -19.5% and a 34.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and Rani Therapeutics Holdings. Mediwound has an analyst consensus of Strong Buy, with a price target consensus of $28.67, a 43.5% upside from current levels. In a report issued on May 19, Craig-Hallum also initiated coverage with a Buy rating on the stock.
Yahoo
14-05-2025
- Business
- Yahoo
XPeng Inc. Sponsored ADR (XPEV) Stock Falls Amid Market Uptick: What Investors Need to Know
XPeng Inc. Sponsored ADR (XPEV) closed at $20.77 in the latest trading session, marking a -1.66% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.73%. Meanwhile, the Dow lost 0.64%, and the Nasdaq, a tech-heavy index, added 1.61%. The company's stock has climbed by 0.19% in the past month, falling short of the Auto-Tires-Trucks sector's gain of 20.69% and the S&P 500's gain of 9.07%. Analysts and investors alike will be keeping a close eye on the performance of XPeng Inc. Sponsored ADR in its upcoming earnings disclosure. The company's earnings report is set to go public on May 21, 2025. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.29 per share and revenue of $10.9 billion, indicating changes of +65.48% and +92.21%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for XPeng Inc. Sponsored ADR. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. XPeng Inc. Sponsored ADR is currently sporting a Zacks Rank of #3 (Hold). The Automotive - Foreign industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 225, positioning it in the bottom 9% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report XPeng Inc. Sponsored ADR (XPEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
